Erlotinib (Tarceva) is first generation of oral EGFR-TKIs.3 Before this work, we performed a meta-analysis to determine the efficacy of erlotinib combine with chemotherapy (CT) or alone in advanced NSCLC.4 Nevertheless, the toxicity of erlotinib in advanced NSCLC patients was not clear. This evidence concerns the gene EGFR and non-small cell lung carcinoma.